iRhythm (IRTC) vs Penumbra (PEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Penumbra (PEN) has outperformed iRhythm (IRTC) over the past year, gaining 22.2% versus a loss of 39.6%. Over five years, IRTC leads with a +47.6% price change compared with +19.3% for PEN. Penumbra is the larger company by market cap ($12.58 billion vs $3.52 billion), about 3.6 times the size, while iRhythm is growing revenue faster (+26.2% vs +17.5%).
On valuation, Penumbra trades at a lower forward P/E (52.1x vs 83.3x for iRhythm). Penumbra converts more of its revenue into profit, with a net margin of 12.7% versus -6.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRTC | PEN |
|---|---|---|
| Share price | $106.70 | $319.40 |
| Market cap | $3.52B | $12.58B |
| 1-day change | +4.00% | +0.59% |
| YTD return | -39.87% | +2.73% |
| 1-year return | -39.57% | +22.19% |
| 5-year return | +47.60% | +19.29% |
| P/E ratio (TTM) | — | 78.48 |
| Forward P/E | 83.26 | 52.09 |
| EPS (TTM) | $-0.44 | $4.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $747.14M | $1.40B |
| Revenue growth (YoY) | +26.24% | +17.50% |
| Net income (latest FY) | $-44.55M | $177.69M |
| Gross margin | 70.57% | 67.14% |
| Operating margin | -7.68% | 13.48% |
| Net margin | -5.96% | 12.66% |
| 52-week high | $212.00 | $362.41 |
| 52-week low | $100.70 | $221.26 |
| Distance from 52-week high | -49.67% | -11.87% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +63.01% | +13.21% |
| Average volume | 568.57K | 354.95K |
| Shares outstanding | 32.96M | 39.39M |
| Employees | 2,400 | 4,700 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Penumbra is about 3.6 times larger than iRhythm by market value ($12.58B vs $3.52B).
- PEN has outperformed IRTC by 61.8 percentage points over the past year.
- Penumbra is more profitable, keeping 12.7 cents of every revenue dollar as net income versus -6.0 cents for iRhythm.
- iRhythm grew revenue faster in its latest fiscal year (+26.24% vs +17.50%).
About iRhythm
IRTC stock →iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.
Health Care · Medical/Dental Instruments · 2,400 employees
About Penumbra
PEN stock →Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Health Care · Medical/Dental Instruments · 4,700 employees
IRTC vs PEN FAQ
Which is bigger, iRhythm or Penumbra?
Penumbra (PEN) is larger, with a market capitalization of $12.58B compared with $3.52B for iRhythm (IRTC).
Which stock has performed better over the past year, IRTC or PEN?
PEN returned +22.19% over the past 12 months, compared with -39.57% for IRTC (price return, excluding dividends). Past performance does not predict future results.
Are iRhythm and Penumbra in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.